BioSpace News Archive

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, provided a corporate update and announced financial results for the third quarter ended September 30, 2022.

Arbe Robotics Ltd., a global leader in next-generation 4D Imaging Radar Solutions, announced financial results for its third quarter ended September 30, 2022.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced acceleration of opaganib’s development program for protection against radiation injury and cancer radiotherapy.

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2022.

CytoSorbents Corporation (NASDAQ: CTSO) announced that 40 of the targeted 120 patients have been enrolled in the Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial, achieving the first enrollment milestone and triggering a pre-specified Data and Safety Monitoring Board (DSMB) review.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended September 30, 2022.

Stoke Therapeutics, Inc. today reported financial results for the third quarter of 2022 and provided business updates, including positive data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome.

Kezar Life Sciences, Inc. today announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib in active lupus nephritis (LN) at the American College of Rheumatology (ACR) Convergence 2022 in Philadelphia, PA.

Captor Therapeutics S.A. (WSE: CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announces a worldwide drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (Ono), to develop novel small molecule degrader drugs against a currently undrugged target of interest in neurodegenerative diseases.

The Alzheimer’s Association is disappointed by the topline Phase 3 data reported today by Genentech and Roche from the GRADUATE Phase 3 global clinical trials of gantenerumab.